Why the study?
Does revascularization with percutaneous coronary intervention improve mortality, cardiovascular events, ejection fraction, angina, or quality of life compared to guideline-directed medical therapy alone in patients with chronic coronary artery disease and heart failure?
Does revascularization with percutaneous coronary intervention improve mortality, cardiovascular events, ejection fraction, angina, or quality of life compared to guideline-directed medical therapy alone in patients with chronic coronary artery disease and heart failure?
Current evidence supports using percutaneous coronary intervention to improve angina and quality of life in patients with chronic coronary disease and heart failure, but there is insufficient data to show benefits in mortality, cardiovascular events, or ejection fraction over medical therapy alone.
Answers are grounded in this paper and cite their sources.
PCI may relieve angina in chronic coronary disease with heart failure; leaves open mortality, event, and ejection fraction benefits versus medical therapy.
The role of revascularization and percutaneous coronary intervention (PCI) in patients with acute coronary syndrome is well established. However, the incremental value of revascularization over guideline-directed medical therapy is controversial. Currently available data supports the use of PCI to improve angina and quality of life for chronic coronary disease and heart failure (HF). However, there is insufficient data to support revascularization with PCI to improve mortality, reduce cardiovascular events, or improve ejection fraction over medical therapy alone. Additional trials are necessary to identify HF patients who may benefit from revascularization, and the optimal revascularization strategy for this population.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: